Anti-gay bias hindered Toronto police as a serial killer roamed
14 Apr, 2021 01:20 AM
6 minutes to read
A mural in the Gay Village area of Toronto, where five victims disappeared. Photo / Aaron Vincent Elkaim, The New York Times
A mural in the Gay Village area of Toronto, where five victims disappeared. Photo / Aaron Vincent Elkaim, The New York Times
New York Times
By: Ian Austen
An inquiry found that systemic discrimination within the Toronto police interfered with efforts to catch a serial killer who targeted gay men, mostly of Middle Eastern or South Asian descent. A 2-1/2-year investigation of the Toronto police has found that systemic discrimination within the force helped a serial killer who murdered eight gay men, mostly of Middle Eastern or South Asian descent, evade detection over a span of seven years.
WASHINGTON, DC – House Majority Leader Steny H. Hoyer (MD) released the following statement today following two separate incidents of police misconduct and
Stop-work meeting of Auckland port workers over safety concerns
12 Apr, 2021 08:34 PM
3 minutes to read
There have been three deaths at the port in recent years. Photo / Michael Craig
A stop-work meeting of Ports of Auckland s front line workers is underway to discuss systemic health and safety issues uncovered at the country s main imports gateway. About 140 members of the Maritime Union of New Zealand are attending. Despite being invited, no company representatives have shown.
The union has about 164 stevedore members but some could not attend because of work commitments, general secretary Craig Harrison said.
The port company has been approached for comment.
(0)
NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs.
The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS) score. The Company plans to present initial data from this study by year-end 2021.
In addition to the KD025-215 trial, an ongoing, double-blind, placebo-controlled Phase 2 clinical trial of belumosudil (KD025-209) is currently enrolling 60 adults with dcSSc. Patients are randomized to receive belumosudil 200 mg once daily (QD), belumosudil 200 mg BID or placebo.